Table 2.

Urinary oxalate on high-oxalate diet (day −1) and average change between placebo and oxalate decarboxylase treatment periods

Subject Identification, n=33Urinary Oxalate High-Oxalate Diet,a 24-h Urine (mg/24 h)Urinary Oxalate (Oxalate Decarboxylase Minus Placebo),b 24-h Urine (mg/24 h)Reduction,c %
900852.8−19.7541.19
903043.1−16.7538.42
903245.8−6.65d21.28d
900951.9−16.736.15
900737−15.8535.3
901246.7−13.6534.08
900651.9−14.5534.07
901940.5−11.933.38
901748.4−15.8532.75
901858.1−16.7531.97
902858.1−15.931.12
901142.2−10.5530.36
901541.4−10.529.13
900451.9−10.9527.97
902440.5−10.527.78
902950.2−13.226.77
900144−9.6525.23
901437−7.524.71
902052.8−10.1523.52
900342.2−7.4521.16
902140.5−8.3520.42
903337.8−8.7519.13
900544−718.09
901629.9−5.7517.64
902355.5−5.2516.13
902742.2−6.1516.06
902647.5−6.615.62
901035.2−3.0513.59
903137−2.65d8.14d
901342.2−3.459.13
900231.7−2.256.47
90224400
902550.22.15−6.78
  • a Mean of urinary oxalate during equilibration period on high-oxalate diet (day −1) immediately preceding the administration of the study drug.

  • b The values represent the difference of urinary oxalate (milligrams per 24 hours) between placebo and oxalate decarboxylase treatment periods.

  • c The values represents the percent reduction in urinary oxalate calculated as [(mean placebo – mean oxalate decarboxylase)/mean placebo] ×100.

  • d Because of an error in sample pooling upon urine collection, the day 1 collections of Subject 9031 and Subject 9032 were excluded from calculation.